Biomaterials for intranasal and inhaled vaccine delivery.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36987501.
- Also identified by DOI 10.1038/s44222-022-00012-6 and PMC identifier 10041562.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Delivery of vaccines by nasal sprays may enable more robust, protective mucosal immune responses against infectious diseases, such as COVID-19, compared with intramuscular injection. In this Comment, we highlight how biomaterials can be designed to allow intranasal and inhaled vaccination.